UMIN ID: UMIN000001547
Registered date:03/12/2008
Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancer
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | colorectal cancer |
Date of first enrollment | 2008/09/01 |
Target sample size | 400 |
Countries of recruitment | Japan |
Study type | Observational |
Intervention(s) |
Outcome(s)
Primary Outcome | Response rate, Time to Treatment failure, Adverse events rate, Progression free survival, Overall survival |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | Not applicable |
---|---|
Age maximum | Not applicable |
Gender | Male and Female |
Include criteria | |
Exclude criteria | 1)Prior bevacizumab administration 2)FOLFIRI+bevacizumab in patients with previous CPT-11-based chemotherapy, or FOLFOX+bevacizumab in patients with previous L-OHP-based chemotherapy |
Related Information
Primary Sponsor | Tsukuba Cancer Clinical Trial Group |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Tsukuba Cancer Clinical Trial Group |
Secondary ID(s) |
Contact
public contact | |
Name | Toshikazu Moriwaki |
Address | Japan |
Telephone | |
Affiliation | University of Tsukuba Gastroenterology |
scientific contact | |
Name | Ichinosuke Hyodo |
Address | 1-1-1 Tennodai, Tsukuba-shi, Ibaraki-ken, Japan Japan |
Telephone | |
Affiliation | University of Tsukuba Gastroenterology |